Table 1.
Signatures derived from gene expression data
| Reference | Cancer | Signatures | Notes |
|---|---|---|---|
| Ayers et al.17 | pan-cancer | TIGIT, CD27, CD8A, PDCD1LG2, LAG3, CD274, CXCR6, CMKLR1, NKG7, CCL5, PSMB10, IDO1, CXCL9, HLA-DQA1, CD276, STAT1, HLA-DRB1, HLA-E | T cell inflammation |
| Rooney et al.14 | pan-cancer | GZMA, PRF1 | cytolytic activity |
| Rooney et al.14 | pan-cancer | B2M, HLA-A, HlA-B, HLA-C, CASP8 | antigen presentation |
| Jiang et al.16 | melanoma and NSCLC | TIDE score | – |
| Lemvigh et al.18 | AML | ZNF683 | expressed in CE8+ effector and memory T cells |
| Helmink et al.20 | melanoma | CD79B, CD1D, CCR6, LAT, SKAP1, CETP, EIF1AY, RBP8, PTGDS | TLS-related genes |
| Hugo et al.25 | melanoma | IPRES: GSVA score from 21 curated gene sets | – |
| Freeman et al.21 | melanoma | MAP4K, TBX3 | gene pair expressed in immune and tumor cell |
| Auslander et al.22 | melanoma | IMPRES: score derived from the logical relationship of 15 gene pairs | – |
| Hwang et al.142 | NSCLC | CBLB, CCR7, CD27, CD48, FOXO1, FYB, HLA-B, HLA-G, IFIH1, IKZF4, LAMP3, NFKBIA, SAMHD1 | M1 Signatures |
| – | – | HLA-DOA, GPR18, STAT1 | peripheral T cell |
| – | – | CD137, PSMB9 | – |
| van Galen et al.143 | AML | NPTX2, H1F0, EMP1, MEIS1, CALCRL, TPSD1, TPT1, CRHBP, CLNK, TSC22D1, DST, NRIP1, ABCB1, GABRA4, ZBTB20, ABCA9, TPSB2, KMT2A, FAM30A, MEF2C, TMEM74, PDZRN4, ST3GAL1, XIRP2, RBPMS, TMEM25, C20orf203, GNG11, SLC6A13, HOPX | HSC-like |
| – | – | CDK6, HSP90AB1, SPINK2, EEF1B2, PCNP, TAPT1-AS1, HINT1, LRRC75A-AS1, DSE, PEBP1, LOC107984974, H2AFY, EEF1A1, SMIM24, PSME1, SOX4, LINC01623, EEF1G, EBPL, EIF4B, PARP1, MEST, TMEM70, TFDP2, ATP5G2, NAP1L1, MSI2, TPM4, SPN, SELL | progenitor-like |
| Wang et al.144 | melanoma and GBM | CXCL9, CXCL10, CXCL11, CXCR3, CD3, CD4, CD8a, CD8b, CD274, PDCD1, CXCR4, CCL5 | hot tumor-related gene |
| – | – | CXCL1, CXCL2, CCL20 | cold tumor-related genes |